297 related articles for article (PubMed ID: 26824319)
1. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in
Hartman ML; Rozanski M; Osrodek M; Zalesna I; Czyz M
Lab Invest; 2017 Feb; 97(2):217-227. PubMed ID: 28067893
[TBL] [Abstract][Full Text] [Related]
3. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
5. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
6. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
Hartman ML; Czyz M
Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
9. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
10. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.
Poindexter KM; Matthew S; Aronchik I; Firestone GL
Cell Biol Toxicol; 2016 Apr; 32(2):103-19. PubMed ID: 27055402
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
Shabna A; Antony J; Vijayakurup V; Saikia M; Liju VB; Retnakumari AP; Amrutha NA; Alex VV; Swetha M; Aiswarya SU; Jannet S; Unni US; Sundaram S; Sherin DR; Anto NP; Bava SV; Chittalakkottu S; Ran S; Anto RJ
Cell Mol Life Sci; 2022 Aug; 79(9):478. PubMed ID: 35948813
[TBL] [Abstract][Full Text] [Related]
12. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
13. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
16. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
18. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway.
Lin M; Bi H; Yan Y; Huang W; Zhang G; Zhang G; Tang S; Liu Y; Zhang L; Ma J; Zhang J
Oncotarget; 2017 Apr; 8(14):23436-23447. PubMed ID: 28423582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]